Skip to main content
SpringerLink
Log in

Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors

  • Chapter
Integration of Pharmaceutical Discovery and Development

Part of the book series: Pharmaceutical Biotechnology ((PBIO,volume 11))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ashorn, P., McQuade, T. J., Thaisrivongs, S., Tomasselli, A. G., Tarpley, W. G., and Moss, B., 1990, An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection, Proc. Natl. Acad. Sci. USA 87:7472–7476.

    CAS  PubMed  Google Scholar 

  • Baba, M., Yuasa, S., Niwa, T., Yamamoto, M., Yabuuchi, S., Takashima, H., Ubasawa, M., Tanaka, H., Miyasaka, T., Walker, R. T., Balzarini, J., DeClerco, G., and Shigeta, S., 1993, Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding, Biochem. Pharmacol. 45:2507–2512.

    CAS  PubMed  Google Scholar 

  • Bourinbaiar, A. S., Tan, X., and Nagorny, R., 1993, Effect of the oral anticoagulant, warfarin, on HIV-1 replication and spread, AIDS 7:129–130.

    CAS  PubMed  Google Scholar 

  • Chong, K. T., 1996, Recent advances in HIV-1 protease inhibitors, Exp. Opin. Invest. Drugs 5:115–124.

    Google Scholar 

  • Darke, P. L., and Huff, J. R., 1994, HIV protease inhibitors target for the treatment of AIDS, in: Advances in Pharmacology, Volume 25 (T. J. August, M. W. Ander, and F. Murad, eds.), Academic Press, San Diego, pp. 399–454.

    Google Scholar 

  • Debouck, C., and Metcalf, B. W., 1990, Human immunodeficiency virus protease: A target for AIDS therapy, Drug Dev. Res. 21:1–17.

    Article  CAS  Google Scholar 

  • DeCamp, D. L., Babe, L. M., Salto, R., Lucich, J. L., Koo, M. S., Kahl, S. B., and Craik, C. S., 1992, Specific inhibition of HIV-1 protease by boronated porphyrins, J. Med. Chem. 35:3426–3428.

    Google Scholar 

  • Epps, D. E., Raub, T. J., and Kezdy, F. J., 1995, A general, wide-range spectrofluorometric method for measuring the site-specific affinities of drugs toward human serum albumin, Anal. Biochem. 227:342–350.

    Article  CAS  PubMed  Google Scholar 

  • Greenlee, W. J., 1990, Renin inhibitors, Med. Res. Rev. 10:173–236.

    CAS  PubMed  Google Scholar 

  • He, X. M., and Carter, D. C., 1992, Atomic structure and chemistry of human serum albumin, Nature 358:209–215.

    Article  CAS  PubMed  Google Scholar 

  • Hirsh, J., Dalen, J. E., Deykin, D., Poller, L., and Bussey, H., 1992, Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range, Chest 108:231S–246S.

    Google Scholar 

  • Huff, J. R., 1991, HIV protease: A novel chemotherapeutic target for AIDS, J. Med. Chem. 34:2305–2314.

    Article  CAS  PubMed  Google Scholar 

  • Hyland, L. J., Tomaszek, T. A., Jr., Roberts, G. D., Carr, S. A., Magaard, V. W., Bryan, H. L., Fakhoury, S. A., Moore, M. L., Minnich, M. D., Culp, J. S., DesJarlais, R. L., and Meek, T. D., 1991a. Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange, Biochemistry 30:8441–8453.

    CAS  PubMed  Google Scholar 

  • Hyland, L. J., Tomaszek, T. A., Jr., and Meek, T. D., 1991b, Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism, Biochemistry 30:8454–8463.

    CAS  PubMed  Google Scholar 

  • Jaskolski, M., Tomasselli, A. G., Sawyer, T. K., Staples, D. G., Heinrikson, R. L., Schneider, J., Kent, S. B., and Wlodawer, A., 1991, Structure at 2.5-Ã… resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor, Biochemistry 30:1600–1609.

    Article  CAS  PubMed  Google Scholar 

  • Johnston, M. I., and Hoth, D. F., 1993, Present status and future prospects for HIV therapies, Science 260:1286–1293.

    CAS  PubMed  Google Scholar 

  • Kageyama, S., Anderson, B. D., Hoesterey, B. L., Hayashi, H., Kiso, Y., Flora, K. P., and Mitsuya, H., 1994, Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins, Antimicrob. Agents Chemother. 38:1107–1111.

    CAS  PubMed  Google Scholar 

  • Koeplinger, K. A., and Zhao, Z., 1996, Chromatographic measurement of drug-protein interaction: Determination of HIV protease inhibitor-serum albumin association, Anal. Biochem. 243:66–73.

    Article  CAS  PubMed  Google Scholar 

  • Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A. F., Scolnick, E. M., and Sigal, I. S., 1988, Active human immunodeficiency virus protease is required for viral infectivity, Proc. Natl. Acad. Sci. USA, 85:4686–4690.

    CAS  PubMed  Google Scholar 

  • Louis, J. M., Smith, C. A., Wondrak, E. M., Mora, P. T., and Oroszlan, S., 1989, Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity, Biochem. Biophys. Res. Commun. 164:30–38.

    Article  CAS  PubMed  Google Scholar 

  • Lunney, E. A., Hagen, S. E., Domagala, J. M., Humblet, C., Kosinski, J., Tait, B. D., Warmus, J. S., Wilson, M., Ferguson, D., Hupe, D., Tummino, P. J., Baldwin, E. T., Bhat, T. N., Liu, B., and Erickson, J. W., 1994, A novel nonpeptide HIV-1 protease inhibitor: Elucidation of the binding mode and its application in the design of related analogues, J. Med. Chem. 37:2664–2677.

    Article  CAS  PubMed  Google Scholar 

  • Meek, T. D., 1992, Inhibitors of HIV-1 protease, J. Enz. Inhib. 6:65–98.

    CAS  Google Scholar 

  • Nagashima, R., and Levi, G., 1969, Comparative pharmacokinetics of coumarin anticoagulants V: Kinetics of warfarin elimination in rat, dog, and rhesus monkey compared to man, J. Pharm. Sci. 58:845–849.

    CAS  PubMed  Google Scholar 

  • Oroszlan, S., and Luftig, R. B., 1990, Retroviral proteinases, Curr. Top. Microb. Immunol. 157:153–185.

    CAS  Google Scholar 

  • Peng, C., Ho, B. K., Chang, T. W., and Chang, N. T., 1989, Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity, J. Virol. 63:2550–2556.

    CAS  PubMed  Google Scholar 

  • Plattner, J. J., and Norbeck, D. W., 1990, Obstacles to drug development from peptide leads, in: Drug Discovery Technologies (C. R. Clark and W. H. Moos, eds.), pp. 92–120, Ellis Horwood, Chichester.

    Google Scholar 

  • Redshaw, S., 1994, Inhibitors of HIV proteinase, Exp. Opin. Invest. Drugs 3:273–286.

    CAS  Google Scholar 

  • Romines, K. R., Watenpaugh, K. D., Tomich, P. K., Howe, W. J., Morris, J. K., Lovasz, K. D., Mulichak, A. M., Finzel, B. C., Lynn, J. C., Horng, M.-M., Schwende, F. J., Ruwart, M. J., Zipp, G. L., Rush, B. D., Wilkinson, K. F., Possert, P. G., Dalga, R. J., and Hinshaw, R. R., 1995a, Use of medium-sized cycloalkyl rings to enhance secondary binding: Discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors, J. Med. Chem. 38:1884–1891.

    CAS  PubMed  Google Scholar 

  • Romines, K. R., Watenpaugh, K. D., Howe, W. J., Tomich, P. K., Lovasz, K. D., Morris, J. K., Janakiraman, M. N., Lynn, J. C., Horng, M.-M., Chong, K. T., Hinshaw, R. R., and Dolak, L. A., 1995b, Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure, J. Med. Chem. 38:4463–4473.

    CAS  PubMed  Google Scholar 

  • Skulnick, H. I., Johnson, P. D., Howe, W. J., Tomich, P. K., Chong, K. T., Watenpaugh, K. D., Janakiraman, M. N., Dolak, L. A., McGrath, J. P., Lynn, J. C., Horng, M.-M., Hinshaw, R. R., Zipp, G. L., Ruwart, M. J., Schwende, F. J., Zhong, W. Z., Padbury, G. E., Dalga, R. J., Shiou, L., Possert, P. G., Rush, B. D., Wilkinson, K. F., Howard, G. M., Toth, L. N., Williams, M. G., Kakuk, T. J., Cole, S. L., Zaya, R. M., Lovaz, K. D., Morris, J. K., Romines, K. R., Thaisrivongs, S., and Aristoff, P. A., 1995, Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors, J. Med. Chem. 38:4968–4971.

    CAS  PubMed  Google Scholar 

  • Thaisrivongs, S., 1994, HIV protease inhibitors, Annu. Rep. Med. Chem. 17:133–144.

    Google Scholar 

  • Thaisrivongs, S., Tomasselli, A. G., Moon, J. B., Hui, J., McQuade, T. J., Turner, S. R., Strohbach, J. W., Howe, W. J., Tarpley, W. G., and Heinrikson, R. L., 1991, Inhibitors of the protease from human immunodeficiency virus: Design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity, J. Med. Chem. 34:2344–2356.

    CAS  PubMed  Google Scholar 

  • Thaisrivongs, S., Tomich, P. K., Watenpaugh, K. D., Chong, K. T., Howe, W. J., Yang, C. P., Strohbach, J. W., Turner, S. R., McGrath, J. P., Bohanon, M. J., Lynn, J. C., Mulichak, A. M., Spinelli, P. A., Hinshaw, R. R., Pagano, P. J., Moon, J. B., Ruwart, M. J., Wilkinson, K. F., Rush, B. D., Zipp, G. L., Dalga, R. J., Schwende, F. J., Howard, G. M., Padbury, G. E., Toth, L. N., Zhao, Z., Koeplinger, K. A., Kakuk, T. J., Cole, S. L., Zaya, R. M., Piper, R. C., and Jeffery, P., 1994, Structure-based design of HIV protease inhibitors: 4-Hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptide inhibitors, J. Med. Chem. 37:3200–3204.

    Article  CAS  PubMed  Google Scholar 

  • Thaisrivongs, S., Watenpaugh, K. D., Howe, W. J., Tomich, P. K., Dolak, L. A., Chong, K. T., Turner, S. R., Strohbach, J. W., Mulichak, A. M., Janakiraman, M. N., Moon, J. B., Lynn, J. C., Horng, M.-M., Hinshaw, R. R., and Pagoan, P. J., 1995, Structure-based design of HIV protease inhibitors: Novel carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors, J. Med. Chem. 38:3624–3637.

    Article  CAS  PubMed  Google Scholar 

  • Thaisrivongs, S., Skulnick, H. I., Turner, S. R., Strohbach, J. W., Tommasi, R. A., Johnson, P. D., Aristoff, P. A., Judge, T. M., Gammill, R. B., Morris, J. K., Romines, K. R., Crusciel, R. A., Hinshaw, R. R., Chong, K. T., Tarpley, W. G., Poppe, S. M., Slade, D. E., Lynn, J. C., Horng, M.-M., Tomich, P. K., Seest, E. P., Dolak, L. A., Howe, W. J., Howard, G. M., Schwende, F. J., Toth, L. N., Padbury, G. E., Wilson, G. J., Shiou, L., Zipp, G. L., Wilkinson, K. F., Rush, B. D., Ruwart, M. J., Koeplinger, K. F., Zhao, Z., Cole, S., Zaya, R. M., Kakuk, T. J., Janakiraman, M. N., and Watenpaugh, K. D., 1996a, Structure-based design of HIV protease inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptic inhibitors, J. Med. Chem. 39:4349–4353.

    CAS  PubMed  Google Scholar 

  • Thaisrivongs, S., Romero, D. L., Tommasi, R. A., Janakiraman, M. N., Strohbach, J. W., Turner, S. R., Biles, C., Morge, R. R., Johnson, P. D., Aristoff, P. A., Tomich, P. K., Lynn, J. C., Horng, M.-M., Chong, K. T., Hinshaw, R. R., Howe, W. J., Finzel, B. D., and Watenpaugh, K. D., 1996b, Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective non-peptic inhibitors, J. Med. Chem. 39:4630–4642.

    CAS  PubMed  Google Scholar 

  • Tomasselli, A. G., Hui, J. O., Sawyer, T. K., Staples, D. J., Bannow, C., Reardon, I. M., Howe, W. J., DeCamp, D. L., Craik, C. S., and Heinrikson, R. L., 1990, Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2, J. Biol. Chem. 265:14675–14683.

    CAS  PubMed  Google Scholar 

  • Tomasselli, A. G., Thaisrivongs, S., and Heinrikson, R. L., 1996, Discovery and design of HIV protease inhibitors as drugs for treatment of AIDS, Adv. Antiviral Drug Des. 2:173–228.

    CAS  Google Scholar 

  • Tummino, P. J., Ferguson, D., and Hupe, D., 1994a, Competitive inhibition of HIV-1 protease by 4-hydroxy-benzopyran-2-ones and by 4-hydroxy-6-phenylpyran-2-ones, Biochem. Biophys. Res. Commun. 200:1658–1664.

    Article  CAS  PubMed  Google Scholar 

  • Tummino, P. J., Ferguson, D., and Hupe, D., 1994b, Competitive inhibition of HIV-1 protease by warfarin derivatives, Biochem. Biophys. Res. Commun. 201:290–294.

    Article  CAS  PubMed  Google Scholar 

  • Vara Prasad, J. V. N., Para, K. S., Lunney, E. A., Ortwine, D. F., Dunbar, J. B., Jr., Ferguson, D., Tummino, P. J., Hupe, D., Tait, B. D., Domagala, J. M., Humblet, C., Bhat, T. N., Liu, B., Guerin, D. M. A., Baldwin, E. T., Erickson, J. W., and Sawyer, T. K., 1994, Novel series of achiral, low molecular weight, and potent HIV-1 protease inhibitors, J. Am. Chem. Soc. 116:6989–6990.

    Article  CAS  Google Scholar 

  • Vara Prasad, J. V. N., Para, K. S., Tummino, P. J., Ferguson, D., McQuade, T. J., Lunney, E. A., Rapundalo, S. T., Batley, B. L., Hingorani, G., Domagala, J. M., Gracheck, S. J., Bhat, T. N., Liu, B., Baldwin, E. T., Erickson, J. W., and Sawyer, T. K., 1995, Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H-pyran-3-yl)thiomethanes that span P1–P2’ subsites in a unique mode of active site binding, J. Med. Chem. 38:898–905.

    Google Scholar 

  • West, M. L., and Fairlie, D. P., 1995, Targeting HIV-1 protease: A test of drug-design methodologies, Trends Pharm. Sci. 16:67–75.

    Article  CAS  PubMed  Google Scholar 

  • Wilkinson, G. R., 1986, Plasma binding and hepatic drug elimination, in: Drug-Protein Binding (M. M. Reidenberg and S. Erill, eds.), pp. 299–316, Praeger Scientific, New York.

    Google Scholar 

  • Williams, R. L., Schary, W. L., Blaschke, M. D., Meffin, P. J., Melmon, K. L., and Rowland, M., 1976, Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin, Clin. Pharmacol. Ther. 20:9097.

    Google Scholar 

  • Yacobi, A., and Levi, G., 1975, Comparative pharmacokinetics of coumarin anticoagulants XIV: Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats, J. Pharm. Sci. 64:1660–1664.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacia & Upjohn, Inc., Kalamazoo, Michigan, 49007

    Guy E. Padbury, Gail L. Zipp, Francis J. Schwende, Zhiyang Zhao, Kenneth A. Koeplinger, Kong Teck Chong, Thomas J. Raub & Suvit Thaisrivongs

Authors
  1. Guy E. Padbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gail L. Zipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francis J. Schwende
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhiyang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth A. Koeplinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kong Teck Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas J. Raub
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Suvit Thaisrivongs
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Kansas, Lawrence, Kansas

    Ronald T. Borchardt

  2. Merck Research Laboratories, West Point, Pennsylvania

    Roger M. Freidinger

  3. ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts

    Tomi K. Sawyer

  4. Smith Kline Beecham, Collegeville, Pennsylvania

    Philip L. Smith

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Padbury, G.E. et al. (2002). Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors. In: Borchardt, R.T., Freidinger, R.M., Sawyer, T.K., Smith, P.L. (eds) Integration of Pharmaceutical Discovery and Development. Pharmaceutical Biotechnology, vol 11. Springer, Boston, MA. https://doi.org/10.1007/0-306-47384-4_10

Download citation

  • DOI: https://doi.org/10.1007/0-306-47384-4_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-45743-2

  • Online ISBN: 978-0-306-47384-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation